Shares of Castle Biosciences CSTL were flat in after-market trading after the company reported Q4 results.
Quarterly Results
Earnings per share were down 254.55% year over year to ($0.17), which missed the estimate of ($0.12).
Revenue of $17,299,000 declined by 1.91% from the same period last year, which beat the estimate of $15,740,000.
Looking Ahead
Earnings guidance hasn't been issued by the company for now.
Castle Biosciences hasn't issued any revenue guidance for the time being.
Details Of The Call
Date: Mar 08, 2021
Time: 04:30 PM
ET Webcast URL: https://edge.media-server.com/mmc/p/9pwwmi9c
Technicals
52-week high: $107.69
Company's 52-week low was at $21.01
Price action over last quarter: Up 36.51%
Company Profile
Castle Biosciences Inc is a commercial-stage dermatological cancer company. It is focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The product portfolio of the company includes Cutaneous Melanoma, DecisionDx-Melanoma, DecisionDx-CMSeq, and DecisionDx-PRAME among others.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
